In this randomized controlled trial, among patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, tezepelumab more effectively reduced nasal polyp size and sinonasal symptoms ...

Larger polyps can lead to breathing problems, a loss of taste or smell, and infections. Symptoms include a post-nasal drip, stuffiness, sinus pressure, facial pain, and frequent nosebleeds.

Nasal polyps may cause a feeling of fullness in the face and/or forehead, but usually do not cause pain. Pain in the upper teeth and/or pain in the face and headache. Asthma symptoms often appear ...

Chronic sinusitis with nasal polyps (CRSwNP) accounts for 20 to 33 percent of these cases. Even after surgical treatment, the recurrence rate of CRSwNP remains high, ranging from 20 to 60 percent ...

and facial pressure or pain. Trial results in nasal polyps reported late last year showed that the drug met all of its primary and secondary endpoints, significantly reducing nasal polyp size ...

The need for systemic corticosteroids fell by 88%, and the need for surgery fell by 98%. Nasal polyp and congestion scores fell, along with loss of smell and total symptom scores. SAN DIEGO ...

Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), significantly reduces nasal polyps and congestion in patients with severe, uncontrolled chronic rhinosinusitis ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

In the United States, 2.1% of the population are affected by chronic rhinosinusitis, up to 30% of whom have nasal polyps.8 People with CRSwNP experience symptoms such as nasal obstruction, loss of ...